Leukodystrophy

0
Pipeline Programs
8
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Takeda
TakedaTOKYO, Japan
1 program
The Myelin Disorders Biorepository ProjectN/A
Orchard Therapeutics
1 program
The Myelin Disorders Biorepository ProjectN/A
ME Therapeutics
ME TherapeuticsNEW YORK, NY
1 program
The Myelin Disorders Biorepository ProjectN/A
Ionis Pharmaceuticals
1 program
The Myelin Disorders Biorepository ProjectN/A
Biogen
BiogenCAMBRIDGE, MA
1 program
The Myelin Disorders Biorepository ProjectN/A
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
The Myelin Disorders Biorepository ProjectN/A
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
The Myelin Disorders Biorepository ProjectN/A1 trial
Active Trials
NCT03047369Recruiting12,000Est. Dec 2030
United Therapeutics
United TherapeuticsMD - Silver Spring
1 program
The Myelin Disorders Biorepository ProjectN/A

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Eli Lilly and CompanyThe Myelin Disorders Biorepository Project

Clinical Trials (1)

Total enrollment: 12,000 patients across 1 trials

NCT03047369Eli Lilly and CompanyThe Myelin Disorders Biorepository Project

The Myelin Disorders Biorepository Project

Start: Dec 2016Est. completion: Dec 203012,000 patients
N/ARecruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 12,000 patients
8 companies competing in this space